Abstract
Diabetic macular edema (DME) is a serious vision threating disease in patients with diabetes mellitus. The introduction of antivasoproliferative therapy (anti-VEGF) into ophthalmic practice allowed patients not only to maintain, but also significantly improve visual acuity. Patients with DME may also have ophthalmic complications that require surgery, such as 3-port pars plana vitrectomy. According to some data, at the time of the start of antiangiogenic therapy, 4.5% of patients with DMO have undegone vitrectomy. It is widely known that changing the environment in the vitreous cavity can have a significant impact on the pharmacokinetic parameters of angiogenesis inhibitors, and therefore affect their effectiveness in patients after vitrectomy. In this regard, the question arises concerning the effectiveness of the use of anti-VEGF drugs in vitrectomized eyes. The literature review contains current data from both pharmacokinetic studies of anti-VEGF drugs in animal models with vitrectomized eyes and clinical studies of antivasoproliferative therapy in patients with DME after vitrectomy. Key words: vitrectomy; diabetic macular edema; anti-VEGF; pharmacokinetics; aflibercept; ranibizumab; vitrectomized eyes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
